<DOC>
	<DOCNO>NCT02220244</DOCNO>
	<brief_summary>The purpose study demonstrate superiority MD1003 placebo visual improvement patient suffer chronic visual loss result multiple sclerosis relate optic neuritis .</brief_summary>
	<brief_title>Effect MD1003 Chronic Visual Loss Related Optic Neuritis Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Optic Neuritis</mesh_term>
	<mesh_term>Neuritis</mesh_term>
	<criteria>1 . Diagnosis criterion MS fulfil revise Mc Donald criterion ( 2010 ) 2 . Unior bilateral optic neuropathy bad eye VAâ‰¤ 5/10 confirm 6 month 3 . Worsening visual acuity last three year 4 . Informed consent prior study procedure 5 . Patient age 1875 year 1 . Optic neuritis relapse within three month inclusion 2 . Normal RNFL OCT 3 . Presence ocular pathology ( glaucoma , cataract , retinopathy , anterior uveitis , myopia &gt; 7 dioptrics , intraocular pressure &gt; 20 mm Hg , amblyopia , retinal optic head abnormality ( drusen , tilt disc ) 4 . Bilateral visual acuity &lt; 1/20 5 . Visual impairment cause ocular flutter nystagmus 6 . Pregnancy childbearing potential woman without contraception 7 . Any general chronic handicap disease MS 8 . New treatment introduce less 3 month prior inclusion less 1 month Fampridine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>multiple sclerosis ( MS )</keyword>
	<keyword>optic neuritis</keyword>
	<keyword>visual defect</keyword>
	<keyword>visual loss</keyword>
	<keyword>relapse remit multiple sclerosis ( RRMS )</keyword>
	<keyword>primary progressive multiple sclerosis ( PPMS )</keyword>
	<keyword>secondary progressive multiple sclerosis ( SPMS )</keyword>
</DOC>